康拓医疗：拟收购蝾螈生物约55.5%股权及西安惠才约72.99%的财产份额

Group 1 - Company announced the acquisition of approximately 55.50% equity in Xi'an Salamander Biotechnology Co., Ltd. and about 72.99% of the property interests in Xi'an Huicai Enterprise Management Consulting Partnership for a total price of approximately 84.98 million RMB [1] - Following the transaction, the company and its newly established wholly-owned subsidiary will directly hold 63.0001% of Salamander Biotechnology's equity and indirectly hold 27.0074% through Huicai, resulting in a total ownership of 90.0075% [1] - Salamander Biotechnology will become a subsidiary of the company and will be included in the consolidated financial statements [1] Group 2 - As of the report date, the company's market capitalization is 3 billion RMB [2] - The company's revenue composition for the year 2024 is projected to be 96.82% from medical device manufacturing and 3.18% from other businesses [1]